Cerebrospinal fluid d-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients

European Neuropsychopharmacology

Volumn 18, Issue 5, 2008, Pages 333-338

  Fuchs, Sabine A ^a   De Barse, Martina M J ^a   Scheepers, Floor E ^a   Cahn, Wiepke ^a   Dorland, Lambertus ^a   de Sain van der Velden, Monique G ^a   Klomp, Leo W J ^a   Berger, Ruud ^a   Kahn, René S ^a   de Koning, Tom J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cerebrospinal fluid; d Serine; ; Glycine; ; NMDA receptor; ; Olanzapine; ; Schizophrenia;

Indexed keywords

DEXTRO SERINE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; SERINE;

ADULT; AMINO ACID ANALYSIS; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; GLYCINE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SERINE;

EID: 40849087780     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.12.002     Document Type: Article

References (38)

1. Andreasen N.C., Flaum M., and Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry 49 (1992) 615-623
2. Arvanov V.L., Liang X., Schwartz J., Grossman S., and Wang R.Y. Clozapine and haloperidol modulate N-methyl-d-aspartate- and non-N-methyl-d-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 283 (1997) 226-234
3. Ballard T.M., Pauly-Evers M., Higgins G.A., Ouagazzal A.M., Mutel V., Borroni E., Kemp J.A., Bluethmann H., and Kew J.N. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J. Neurosci. 22 (2002) 6713-6723
4. Bendikov I., Nadri C., Amar S., Panizzutti R., De M.J., Wolosker H., and Agam G. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr. Res. 90 (2007) 41-51
5. Boks M.P., Rietkerk T., van de Beek M.H., Sommer I.E., De Koning T.J., and Kahn R.S. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia. Eur. Neuropsychopharmacol. 17 (2007) 567-572
6. Bruckner H., and Hausch M. Gas chromatographic characterization of free d-amino acids in the blood serum of patients with renal disorders and of healthy volunteers. J. Chromatogr. 614 (1994) 7-17
7. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., Abderrahim H., Bougueleret L., Barry C., Tanaka H., La Rosa P., Puech A., Tahri N., Cohen-Akenine A., Delabrosse S., Lissarrague S., Picard F.P., Maurice K., Essioux L., Millasseau P., Grel P., Debailleul V., Simon A.M., Caterina D., Dufaure I., Malekzadeh K., Belova M., Luan J.J., Bouillot M., Sambucy J.L., Primas G., Saumier M., Boubkiri N., Martin-Saumier S., Nasroune M., Peixoto H., Delaye A., Pinchot V., Bastucci M., Guillou S., Chevillon M., Sainz-Fuertes R., Meguenni S., Aurich-Costa J., Cherif D., Gimalac A., Van Duijn C., Gauvreau D., Ouellette G., Fortier I., Raelson J., Sherbatich T., Riazanskaia N., Rogaev E., Raeymaekers P., Aerssens J., Konings F., Luyten W., Macciardi F., Sham P.C., Straub R.E., Weinberger D.R., Cohen N., and Cohen D. Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13675-13680
8. Daly D.A., and Moghaddam B. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci. Lett. 152 (1993) 61-64
9. Detera-Wadleigh S.D., and McMahon F.J. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol. Psychiatry 60 (2006) 106-114
10. Dunlop D.S., and Neidle A. Regulation of serine racemase activity by amino acids. Brain Res. Mol. Brain Res. 133 (2005) 208-214
11. Evins A.E., Amico E.T., Shih V., and Goff D.C. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J. Neural Transm. 104 (1997) 761-766
12. Farber N.B., Foster J., Duhan N.L., and Olney J.W. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr. Res. 21 (1996) 33-37
13. Fu T.F., Rife J.P., and Schirch V. The role of serine hydroxymethyltransferase isozymes in one-carbon metabolism in MCF-7 cells as determined by (13)C NMR. Arch. Biochem. Biophys. 393 (2001) 42-50
14. Fuchs S.A., Dorland L., De Sain-Van Der Velden M.G., Hendriks M., Klomp L.W., Berger R., and De Koning T.J. d-Serine in the developing human central nervous system. Ann. Neurol. 60 (2006) 476-480
15. Fujii K., Maeda K., Hikida T., Mustafa A.K., Balkissoon R., Xia J., Yamada T., Ozeki Y., Kawahara R., Okawa M., Huganir R.L., Ujike H., Snyder S.H., and Sawa A. Serine racemase binds to PICK1: potential relevance to schizophrenia. Mol. Psychiatry 11 (2006) 150-157
16. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158 (2001) 1367-1377
17. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., and Coyle J.T. d-Cycloserine added to clozapine for patients with schizophrenia. Am. J. Psychiatry 153 (1996) 1628-1630
18. Goldner E.M., Hsu L., Waraich P., and Somers J.M. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can. J. Psychiatry 47 (2002) 833-843
19. Harrison P.J., and Owen M.J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361 (2003) 417-419
20. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L.H., and Iyo M. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 29 (2005) 767-769
21. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., and Iyo M. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 60 (2003) 572-576
22. Herbig K., Chiang E.P., Lee L.R., Hills J., Shane B., and Stover P.J. Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses. J. Biol. Chem. 277 (2002) 38381-38389
23. Heresco-Levy U. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1113-1123
24. Kumashiro S., Hashimoto A., and Nishikawa T. Free d-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases. Brain Res. 681 (1995) 117-125
25. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., and Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25 (2001) 455-467
26. Miyamoto Y., Yamada K., Noda Y., Mori H., Mishina M., and Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J. Neurosci. 21 (2001) 750-757
27. Mohn A.R., Gainetdinov R.R., Caron M.G., and Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (1999) 427-436
28. Morita Y., Ujike H., Tanaka Y., Otani K., Kishimoto M., Morio A., Kotaka T., Okahisa Y., Matsushita M., Morikawa A., Hamase K., Zaitsu K., and Kuroda S. A genetic variant of the serine racemase gene is associated with schizophrenia. Biol. Psychiatry 61 (2007) 1200-1203
29. Olney J.W., and Farber N.B. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J. Clin. Psychiatry 55 Suppl B (1994) 43-46
30. Scheepers F.E., Gispen-De Wied C.C., Westenberg H.G., and Kahn R.S. Effect of olanzapine on glutamate levels in cerebrospinal fluid of patients with schizophrenia. J. Clin. Psychopharmacol. 22 (2002) 333-334
31. Steffek A.E., Haroutunian V., and Meador-Woodruff J.H. Serine racemase protein expression in cortex and hippocampus in schizophrenia. Neuroreport 17 (2006) 1181-1185
32. Strisovsky K., Jiraskova J., Mikulova A., Rulisek L., and Konvalinka J. Dual substrate and reaction specificity in mouse serine racemase: identification of high-affinity dicarboxylate substrate and inhibitors and analysis of the beta-eliminase activity. Biochemistry 44 (2005) 13091-13100
33. Tsai G., van Kammen D.P., Chen S., Kelley M.E., Grier A., and Coyle J.T. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol. Psychiatry 44 (1998) 667-674
34. Tsai G., Lane H.Y., Yang P., Chong M.Y., and Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 55 (2004) 452-456
35. Tsai S.J., Cheng C.Y., Hong C.J., Liao D.L., Hou S.J., Yen F.C., and Liou Y.J. Association study of polymorphisms in glycine transporter with schizophrenia. J. Neural Transm. 113 (2006) 1545-1549
36. Tuominen H.J., Tiihonen J., and Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst. Rev. CD003730 (2006)
37. Wolosker H., Blackshaw S., and Snyder S.H. Serine racemase: a glial enzyme synthesizing d-serine to regulate glutamate-N-methyl-d-aspartate neurotransmission. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13409-13414
38. Yamamoto B.K., and Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14 (1994) 4159-4166